U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT06891456) titled 'Pulse Field Ablation for Post-Infarction Ventricular Tachycardia' on March 12.
Brief Summary: ASCEND is a randomized controlled open-label pilot study evaluating the safety and effectiveness of pulsed field ablation (PFA) with the novel FARAPOINT catheter compared to the standard radiofrequency (RFA) ablation with FlexAbility SE or ThermoCool ST catheter for ablation of ventricular tachycardia (VT) in the patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator (ICD). The study hypothesis is that the PFA ablation is more efficient compared to the RFA technique but retains a comparable safety profile.
Study ...